Trimeris.

PositionTRIANGLE - Brief Article

Steven Skolsky replaced founder Dani Bolognesi (cover story, July 2003) as CEO of Trimeris. Bolognesi will remain with the Durham-based drug maker as vice chairman and chief scientific officer. Trimeris' only product is its AIDS treatment, Fuzeon. Disappointing sales have been blamed on the drug's high cost--about...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT